Ww International, Inc. (WW) · Nov 5, 2026 · Earnings
Beat — Revenue $152.9M vs ~$152.3M consensus; FY EBITDA midpoint raised to $112.5M
WW International’s Q3 earnings narrowly beat revenue expectations, with clinical subscribers and margins improving while the legacy behavioral business continued to contract.
WW is in the middle of a post-bankruptcy business transition: it is shifting from a shrinking traditional behavioral subscription model toward an integrated weight-health platform built around clinical care, GLP-1 access, and higher-value memberships. Its own prior disclosures acknowledged that Clinical growth had not yet offset Behavioral declines.
The quarter modestly cleared the financial bar. Revenue was $152.9 million, narrowly above the published consensus of roughly $152.3 million, while GAAP EPS was $1.51 versus an external estimate near $0.63; the cleaner signal is that full-year Adjusted EBITDA guidance moved up at the midpoint rather than merely being repeated. The revenue beat is small, so this is an execution win, not a decisive turnaround.
| Figure | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Revenue (Financial Highlights) | $152.9M (-11%) | $172.1M | ~$152.3M |
| Clinical subscription revenue (Q3 Business Updates) | $38.0M (+48%) | $25.8M | |
| Behavioral subscription revenue (Selected Financial Data) | $113.9M (-21.5%) | $145.2M | |
| Adjusted EBITDA (Financial Highlights) | $51.7M (+21%) | $42.8M | |
| Net income (Income Statement) | $15.1M | $(57.5M) | |
| End-of-period subscribers (Operational Statistics) | 2.296M (-23.1%) | 2.986M | |
| FY revenue guidance (Fiscal 2026 Guidance) | $625M–$630M | $620M–$635M | |
| FY Adjusted EBITDA guidance (Fiscal 2026 Guidance) | $110M–$115M | $105M–$115M |
The strategic pivot is working, but it is not yet large enough to reverse the top line. Clinical subscription revenue rose 48% to $38.0 million and Clinical subscribers increased 40% to 174,000, while Core+ subscribers rose 16% to 546,000. But Behavioral subscription revenue fell 21.5%, and total subscribers declined 23.1%; the new businesses are improving mix and monetization rather than replacing the lost legacy volume today. 〔0〕
Profitability improved mainly through mix and spending control. Adjusted EBITDA rose 21% to $51.7 million and the company produced positive GAAP net income, helped by lower marketing and corporate spending. However, adjusted gross margin slipped to 74.6% from 75.1%, so the earnings improvement reflects cost discipline and a richer clinical mix more than broad-based operating leverage.
The outlook is a small step up, not a reset. Revenue guidance was narrowed around a slightly higher midpoint, while the Adjusted EBITDA midpoint increased from $110 million to $112.5 million. That supports the view that management is executing better than feared, but the range still implies a business relying on margin discipline while legacy demand remains under pressure.
Bottom line: WW is showing credible progress in Clinical, Core+, and cash earnings, and the raised EBITDA midpoint edges the quarter ahead of expectations. The business is improving its mix faster than it is replacing lost behavioral subscribers, so this strengthens the transition story without rewriting it.
Q4 and full-year 2026 results
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!